Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
VanEck Pharmaceutical ETF
(NQ:
PPH
)
99.10
-0.13 (-0.13%)
Official Closing Price
Updated: 4:15 PM EST, Nov 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about VanEck Pharmaceutical ETF
< Previous
1
2
Next >
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight
↗
November 17, 2025
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.
Via
Benzinga
Topics
ETFs
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs
↗
November 15, 2025
A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
Via
Benzinga
Topics
ETFs
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
↗
November 12, 2025
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
Via
Benzinga
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers
↗
July 29, 2025
Via
Stocktwits
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
↗
July 21, 2025
Via
Stocktwits
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
↗
October 30, 2025
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
Via
Benzinga
Topics
ETFs
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet
↗
October 17, 2025
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.
Via
Benzinga
Topics
ETFs
Government
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
↗
October 13, 2025
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via
The Motley Fool
Topics
ETFs
Government
World Trade
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
↗
September 29, 2025
The U.S. pharmaceutical industry is at the center of a policy maelstrom.
Via
Benzinga
Topics
ETFs
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
↗
September 29, 2025
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
Via
Benzinga
Topics
Government
World Trade
Pharma Tariffs Back In Spotlight On New Trump Threat
↗
September 26, 2025
President Donald Trump threatened 100% tariffs on some drug imports.
Via
Investor's Business Daily
Topics
ETFs
Government
World Trade
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
↗
September 08, 2025
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
Via
Benzinga
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
↗
August 01, 2025
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
Via
Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
↗
July 16, 2025
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via
Benzinga
Topics
Government
World Trade
FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report
↗
July 11, 2025
FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.
Via
Stocktwits
Topics
Government
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
↗
July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via
Benzinga
Topics
Government
World Trade
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
↗
June 20, 2025
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
Via
Benzinga
FDA Aims To Reduce Drug Application Review Time With New Voucher Program
↗
June 17, 2025
The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final...
Via
Stocktwits
Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work
↗
May 20, 2025
The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S.
Via
Investor's Business Daily
Topics
ETFs
Government
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
↗
May 19, 2025
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
Via
Benzinga
Topics
Government
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
↗
May 08, 2025
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Via
Benzinga
Topics
ETFs
Government
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
↗
April 28, 2025
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and...
Via
Stocktwits
Topics
Government
Intellectual Property
Lawsuit
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
↗
April 11, 2025
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
Via
Benzinga
Topics
Government
World Trade
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
↗
February 19, 2025
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
Via
Stocktwits
Topics
Earnings
VanEck Announces Year-End Distributions for VanEck Equity ETFs
December 20, 2024
From
VanEck
Via
Business Wire
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
↗
June 12, 2024
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss...
Via
Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
↗
May 08, 2024
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.
Via
InvestorPlace
A Look At Pharma ETFs Post Q1 Earnings
↗
May 07, 2024
Pharma ETFs have delivered mixed performances over the past month.
Via
Talk Markets
Topics
ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
↗
May 01, 2024
Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest...
Via
Talk Markets
Topics
ETFs
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
↗
April 17, 2024
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
Via
InvestorPlace
Topics
ETFs
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.